Nhịp đập tiền mã hoá - Cổ phiếu Mỹ

SummaryUMCON is an Ondo tokenized stock designed to provide economic exposure linked to United Microelectronics Corporation’s New York Stock Exchange-listed American Depositary Shares, ticker UMC.Eligible users can trade UMCON against Tether through the UMCON/USDT spot market on MEXC. The trading pair allows users to buy or sell UMCON using USDT through MEXC’s spot order book.Trading UMCON is not the same as purchasing UMC American Depositary Shares through a securities broker. UMCON provides to

SummaryUMCON is an Ondo tokenized security designed to provide economic exposure linked to United Microelectronics Corporation’s NYSE-listed American Depositary Shares, which trade under the ticker UMC.UMCON is not issued by United Microelectronics Corporation. It is also not the same legal instrument as a UMC American Depositary Share, or ADS. Holding UMCON does not make a user a directly registered shareholder of UMC and does not provide a direct right to receive the underlying ADS or the ordi

SummaryUnited Microelectronics Corporation is a global semiconductor foundry headquartered in Hsinchu, Taiwan. Its ordinary shares trade on the Taiwan Stock Exchange under 2303, while its American Depositary Shares trade on the New York Stock Exchange under UMC.Technically, the U.S.-listed UMC instrument is an American Depositary Share, or ADS, rather than a separately issued U.S. common share. Each UMC ADS represents five ordinary shares of United Microelectronics Corporation. J.P. Morgan acts

SummaryVRTXON is designed to provide total-return economic exposure linked to Vertex Pharmaceuticals stock, VRTX.Its value should generally move in the same direction as VRTX, but the two prices may not be identical at every moment. VRTX trades through traditional securities markets, while VRTXON/USDT trades through a digital-asset order book on MEXC.Short-term price differences may arise because of market hours, bid-ask spreads, stablecoin pricing, limited token liquidity, corporate actions, mi

SummaryVRTX stock price predictions depend on the durability of Vertex Pharmaceuticals’ cystic fibrosis franchise, growth from CASGEVY and JOURNAVX, the regulatory and commercial outcome for povetacicept, pipeline execution and the proposed acquisition of Crinetics Pharmaceuticals.VRTX closed at approximately $478.84 on July 27, 2026. Rather than presenting one guaranteed target, this forecast uses broad bull, base and bear ranges.PeriodBear scenarioBase scenarioBull scenarioEnd of 2026$380–$440

SummaryVertex Pharmaceuticals enters the second half of 2026 with a strong cystic fibrosis franchise, growing contributions from ALYFTREK, CASGEVY and JOURNAVX, a potentially valuable kidney-disease pipeline and a proposed $10 billion acquisition of Crinetics Pharmaceuticals.The core bullish argument is that Vertex can use durable CF cash flows to build several new commercial franchises. The core bearish argument is that most revenue remains concentrated in CF while new launches, clinical progra

SummaryVRTX and VRTXON provide exposure to the economic performance of Vertex Pharmaceuticals, but they are fundamentally different instruments.VRTX is the Nasdaq-listed common stock of Vertex Pharmaceuticals Incorporated. VRTXON is an Ondo tokenized stock traded against USDT on MEXC. VRTXON is designed to track the total-return economics of VRTX but is not the underlying share and does not provide direct ownership or shareholder voting rights.The choice between them depends on the user’s object

SummaryVRTXON is an Ondo tokenized stock designed to provide economic exposure linked to Vertex Pharmaceuticals stock, ticker VRTX. Eligible users can trade VRTXON against USDT through the VRTXON/USDT market on MEXC.Trading VRTXON is not the same as purchasing traditional VRTX shares through a securities broker. VRTXON does not provide direct ownership or direct shareholder voting rights in Vertex Pharmaceuticals. It also carries additional token, issuer, liquidity, exchange and stablecoin risks

SummaryVRTXON is an Ondo tokenized stock designed to provide eligible users with economic exposure linked to Vertex Pharmaceuticals Incorporated stock, ticker VRTX.VRTXON is not issued by Vertex Pharmaceuticals and is not the same legal instrument as a VRTX share. It does not make the holder a directly registered Vertex shareholder or provide a direct right to receive the underlying VRTX stock.Ondo describes its tokenized stocks as total-return tracking products backed by corresponding stocks, E

SummaryVertex Pharmaceuticals Incorporated is a global biotechnology company listed on the Nasdaq Global Select Market under the ticker VRTX. The company is best known for developing medicines that treat the underlying cause of cystic fibrosis, but its commercial portfolio now also includes CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for moderate-to-severe acute pain.Vertex generated approximately $12.0 billion in total revenue in 2025 and guided for